<DOC>
	<DOC>NCT01160432</DOC>
	<brief_summary>The aim of the study is to examine the tolerability and abuse potential of the diluted methadone solution (5 mg/ml â†’ 2 mg/ml) in combination with naloxone in opioid substitution treatment. Study hypothesis: Treatment with this diluted combination product is safer than with methadone alone (5 mg/ml) and combination product does not precipitate withdrawal symptoms in opioid dependent patients.</brief_summary>
	<brief_title>Naloxone Methadone Combination (NAMEKO)</brief_title>
	<detailed_description />
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>opioid dependence methadone treatment no changes in methadone dose during the last 10 days good treatment compliance according to doctor normal ALAT and AFOS values (increased if double the normal level) severe renal or hepatic failure acute psychosis age under 18 pregnancy legal incompetence severe somatic disease chaotic situation in life medication or disease which is contraindication to study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>opiate dependence</keyword>
	<keyword>methadone</keyword>
	<keyword>naloxone</keyword>
	<keyword>withdrawal symptom</keyword>
	<keyword>substitution treatment</keyword>
</DOC>